Bjørneboe O, Moen F, Nygaard H, Haavik T K, Svensson B
Dept. of Rheumatology, Martina Hansens Hospital, Sandvika, Norway.
Scand J Rheumatol. 1998;27(1):26-31. doi: 10.1080/030097498441137.
The onset of action rate of CPH-82 (Reumacon), was compared with that of auranofin (AUR; Ridaura) in a 36-week randomised, double-blind, multicentre study of 60 patients with rheumatoid arthritis (RA). As compared with respective baseline values, the CPH-82 group manifested significant improvement in grip strength, Ritchie's articular index (RAI), pain ratings, and HAQ (health assessment questionnaire) scores after 8, 12, 24, and 36 weeks of treatment, with the exception of the 24-week HAQ score. The AUR group manifested corresponding improvement in RAI after 8, 12, 24, and 36 weeks. Significant differences in changes from baseline values in favour of the CPH-82 group were found for grip strength at 12 and 24 weeks, RAI score at 8 weeks, VAS score at 8 and 12 weeks, and HAQ score at 8 weeks. The findings suggest CPH-82 to manifest a more rapid onset of action than AUR. The two drugs were similar in tolerance and safety.
在一项针对60例类风湿性关节炎（RA）患者的为期36周的随机、双盲、多中心研究中，对CPH - 82（瑞玛康）与金诺芬（AUR；立达罗）的起效速率进行了比较。与各自的基线值相比，CPH - 82组在治疗8周、12周、24周和36周后，握力、里奇关节指数（RAI）、疼痛评分和健康评估问卷（HAQ）得分均有显著改善，但24周时的HAQ得分除外。AUR组在8周、12周、24周和36周后RAI有相应改善。在12周和24周时的握力、8周时的RAI评分、8周和12周时的视觉模拟评分（VAS）以及8周时的HAQ评分方面，发现CPH - 82组与基线值相比的变化有显著差异，且有利于CPH - 82组。研究结果表明，CPH - 82的起效比AUR更快。两种药物在耐受性和安全性方面相似。
